Format

Send to

Choose Destination
Oncotarget. 2011 Oct;2(10):737-8.

Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia..

Abstract

PI3K signaling is now targeted in first clinical trials in patients with B cell malignancies, including Chronic Lymphocytic Leukemia (CLL), which represent one of the first molecularly targeted therapies for B cell malignancies.

PMID:
22006556
PMCID:
PMC3248155
DOI:
10.18632/oncotarget.341
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center